Siro could be a booster for Biocon

08 Mar 2010 Evaluate

Biocon may gain from a possible alliance with clinical research organisation Siro Clinpharm. Biocon will not only get access to Siro’s huge client base, but the deal will also help its subsidiary Syngene get attractive valuations. Siro offers services ranging from data management, pharmacovigilance, medical writing, bio-statistics, etc. which can bolster Biocon’s clinical trials expertise. Biocon will be able to use Siro’s client base to get more clinical trials work and thus get more projects.

Siro is a strategic fit for Biocon subsidiaries Clinigene and Syngene. Biocon is looking at listing Syngene and if Siro gets acquired and merged with Syngene, the valuations will be better. Syngene does contract research for pharmaceutical companies, while Clinigene manages clinical trials for drug companies.

crackcrack

Biocon Share Price

304.00 5.15 (1.72%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.